Navigation Links
AACR news: Rigosertib Phase 1 results lead to disease-focused Phase 2 development
Date:4/9/2013

Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients. The drug candidate is being developed by Onconova Therapeutics, Inc., of Pennington, NJ.

Overall, 48 patients were included in the Phase I trial with oral rigosertib, and 7 remained on study for at least six months. Six head and neck cancer patients included in this study had failed platinum-based therapies, and 2 of these patients showed a response to Rigosertib one with the disappearance of lung metastasis and another with greater than 50 percent decrease of liver metastasis. These 2 patients have received oral rigosertib treatment for 98 and 48 weeks.

"The results from the head and neck cancer patients are interesting, revealing that the drug worked in a subset of patients," says Antonio Jimeno, MD, PhD, investigator at the University of Colorado Cancer Center and director of the university's Head and Neck Cancer Medical Oncology Program. "To learn more about the relationship between response and genetic make-up of the tumor, we've been investigating molecular correlates in a surrogate Phase 2 trial in patient-derived animal models of head and neck cancer."

As highlighted in the AACR presentation, genetic analysis of tumor samples from the Phase 1 trial and continuing genetic analysis of animal models, performed at both the Colorado Molecular Correlates Laboratory (CMOCO) and Dr. Jimeno's research laboratory, detected several potential biomarkers, including the genes PIK3CA and PTEN, which are both members of the signaling pathway targeted by the drug. Whole-exome sequencing of patient samples also revealed what Jimeno calls, "a short list of core alterations in genes for further exploration as predictive biomarkers."

"These promising results from human trial combined with relevant animal models established in our laboratories are helping us learn more about this drug and its mechanism of action. Based on these studies, we are initiating an 80-patient, multi-institutional Phase 2 trial," says Jimeno. In this trial, tissue samples from patients will be analyzed by sequencing and using other genomic tools to fully explore the predictive capability of these candidate biomarkers.

"We have seen meaningful activity in a subset of patients in the Phase I trial and we confirmed this in the surrogate animal model," Jimeno says. "The hope is that broad genetic analysis will help identify biomarkers for accurately matching the drug with the right patients in the future."

"It's an exciting time for an exciting drug," Jimeno says.


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Good news: Migraines hurt your head but not your brain
2. Grape News: Global Wine Manufacturing Industry Market Research Report from IBISWorld has Been Updated
3. Actos Lawsuit News: Bernstein Liebhard LLP Notes Latest Scheduling Order in Actos Bladder Cancer Litigation
4. Zoloft Lawsuit News: Bernstein Liebhard LLP Notes New Pretrial Order in Federal Zoloft Litigation Establishing Tentative Date for First Bellwether Trial
5. MinuteHound News: Top Three Ways To Save Money With Biometric Time and Attendance Solutions
6. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conferences in Federal Transvaginal Mesh Litigations
7. Da Vinci Robotic Surgery Lawsuit News: Ohio Law Firm Investigates Da Vinci Robotic Surgery Complications as Settlement is Reached in Louisiana Da Vinci Robot Lawsuit
8. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
9. Stryker Hip Replacement Lawsuit News: Mass. Woman Files First Known Federal Stryker ABG II Hip Lawsuit, Rottenstein Law Group Reports
10. ALS patients differ on treatment choices in later phases of disease
11. Reach2HD, a Phase II study in Huntingtons disease, launched
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... , ... According to the American Society of Plastic Surgeons (ASPS), over one ... 5 most popular minimally-invasive cosmetic procedures in the country. With summer close, it’s safe ... next 8-10 weeks. For anyone considering a hair removal procedure, there are a few ...
(Date:3/30/2017)... ... March 30, 2017 , ... Nutrition Education ... and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating ... designed to help nutrition educators and students inform consumers about the health benefits ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has named ... more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers a ... cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box blades. ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Grass pollen is the main cause of hay ... the stuff. The season for grass pollen runs from May to July each year; with ... fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Sports Brand EXOUS ... brace, which retails normally at $29.97; for the remaining days of March, the price ... been reduced to a special price of just $10 (regular retail price $19.97). , ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... 2017 Revenue Prospects by Product Type (Metered ... and Geography Respiratory Inhalers - our new study reveals ... Inhalers market heading? If you are involved in this sector you ... you the potential revenues streams to 2027, assessing data, trends, opportunities ... ...
(Date:3/29/2017)... 29, 2017 Research and Markets has ... Size & Forecast By Type (Insource IONM, Outsource IONM), By ... to their offering. ... The global Intraoperative Neuromonitoring (IONM) market is ... neuromonitoring market is anticipated to witness significant growth in the ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... their offering. ... The global energy-based aesthetic devices market to grow at a CAGR ... Global Energy-Based Aesthetic Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: